Bausch Health Companies Inc. (BHC) Earnings Call Analysis

NYSE · Healthcare · Drug Manufacturers - Specialty & Generic

17/25

Growth 4 Margin 4 Expansion 4 Platform 1 Financial 4

latest quarter score

Earnings Reports

17
Bausch Health (BHC) Q2 2026: EBITDA Margin Jumps 530bps as Salix and Solta Drive Outperformance
July 30, 2026
22
Bausch Health (BHC) Q1 2026: Solta China Revenue Soars 193%, Accelerating Global Growth Leverage
June 16, 2026
13
Bausch Health (BHC) Q3 2025: Solta Surges 25% as Strategic Focus Shifts to Innovation and Deleveraging
June 16, 2026
25
Bausch Health (BHC) Q4 2025: 9% Revenue Growth Anchored by Strategic Acquisitions and Operational Excellence
February 18, 2026
18
Bausch Health (BHC) Q2 2025: Solta Revenue Up 25%, Fueling Margin Expansion and Debt Flexibility
July 30, 2025
11
Bausch Health (BHC) Q1 2025: $7.9B Debt Refinancing Extends Runway, But Tariff and Cash Flow Headwinds Loom
July 04, 2025
Bausch Health (BHC) Q3 2024: Operating Cash Flow Jumps 75% as Portfolio Diversification Drives Guidance Hike
October 30, 2024
Bausch Health (BHC) Q2 2024: Solta Asia Revenue Doubles, Diversification Urgency Rises
August 01, 2024
Bausch Health (BHC) Q1 2024: Solta Surges 23% Organically, Pipeline Execution Anchors Growth Narrative
May 02, 2024
Bausch Health (BHC) Q4 2023: Debt Down $670M as R&D and International Units Drive Strategic Reset
February 22, 2024
Bausch Health (BHC) Q3 2023: Organic Growth Guidance Raised to 6% as Pipeline and Consumables Drive Durable Upside
November 02, 2023
13
Bausch Health (BHC) Q2 2023: Salix Revenue Climbs 11% as Pipeline Acceleration Offsets Margin Pressure
August 03, 2023
Bausch Health (BHC) Q1 2023: Salix Grows 7% as R&D and Marketing Spend Ramps for Pipeline Renewal
May 04, 2023
Bausch Health (BHC) Q4 2022: $3.2B Debt Reduction Reshapes Capital Flexibility Amid Segment Divergence
February 23, 2023

Browse all companies